Evidence map›Paper›PMID 38409268›Full record

ArticleNPJ breast cancer2024

Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.

Silver Alkhafaji, Denise M Wolf, Mark Jesus M Magbanua, Laura J van 't Veer, John W Park, Laura Esserman, Rita A Mukhtar

Open access · goldAbstract read
In one paragraph

Article in NPJ breast cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Silver AlkhafajiDepartment of Labaratory Medicine, University of California, San Francisco, San Francisco, CA, USA. silver.alkhafaji@ucsf.edu.ORCID http://orcid.org/0000-0002-2248-1381
Denise M WolfDepartment of Labaratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
Mark Jesus M MagbanuaDepartment of Labaratory Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2113-3593
Laura J van 't VeerDepartment of Labaratory Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-9838-8298
John W ParkDepartment of Hematology/Oncology, University of California, San Francisco, San Francisco, CA, USA.
Laura EssermanDepartment of Surgery, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9202-4568
Rita A MukhtarDepartment of Surgery, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8079-7846
University of California, San Francisco · US

Funding

Identifying responders to chemotherapy in invasive lobular carcinoma of the breast: development of a multivariable clinical prediction toolK08CA256047 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MUKHTAR, RITA · 2021 to 2025
$1.3M
NCI NIH HHS K08 CA256047
6 · The paper itself

Abstract

This is a secondary data analysis of the TIPPING study, which included 1,121 patients with stage I-III breast cancer who had enumeration of CTCs (by either CellSearch or immunomagnetic enrichment and flow cytometry [IE/FC]) and disseminated tumor cells (DTCs) at the time of surgical resection between 1999 and 2012. The primary endpoint was mean number of CTCs by histology, taking into account method of detection and treatment type, and evaluation of histology specific prognostic cutpoints. Overall, patients with ILC had significantly higher CTC counts than those with IDC, a finding which persisted in the 382 patients with CTC enumeration by IE/FC method. Additionally, among those with primary surgery, patients with ILC had significantly higher mean CTC counts than those with IDC (mean 2.11 CTCs/mL versus 0.71 CTCs/mL respectively, p < 0.001), which persisted on multivariate analysis. Patients with ILC and CTC-high/DTC-high status trended towards reduced DRFS HR = 9.27, 95% CI 0.95-90.5, p = 0.055) and had significantly decreased BCSS (HR = 10.4, 95% CI 1.07-99.7, P = 0.043) compared with those who were CTC-low/DTC-low. In the IDC group, CTC-high/DTC-high status was not associated with either DRFS or BCSS. In neoadjvuantly treated patients, there was no significant difference in CTC counts in the ILC group versus the IDC group (mean 0.89 CTCs/mL versus 1.06 CTCs/mL respectively, p = 0.82). Our findings contribute to the limited literature on CTCs and DTCs in ILC, and suggest that clinical utility and optimal thresholds for CTC and DTC assays may differ by histologic subtype in early-stage breast cancer.

Identifiers

PMID38409268
PMCPMC10897340
OpenAlexW4392154341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.